ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Thursday, 12 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Influx Healthtech Earnings Call: Key Takeaways

Influx Healthtech delivered strong 41% YoY revenue growth in H2 FY26, driven by nutraceuticals, despite margin pressure from aggressive hiring ahead of massive capacity expansion.

Why this was an Alfa AlertNot a filter event. Performance was strong but management did not explicitly state it beat prior guidance by >5%.
Highlights
Revenue growthH2 FY26 revenue grew 41% YoY to ₹80.1cr.
MarginsGross margins dipped to 39% due to RM cost/mix changes.
Demand visibilityStrong demand in nutraceuticals and pet care segments.
Management confidenceHighly optimistic, emphasizing strategic hiring and capacity expansion for FY27.

Growth

FY26 revenue hit ₹146cr; nutraceuticals grew 40% while Ayurvedic products surged 89% YoY.

Outlook

Targeting ₹450-500cr revenue by FY29; new facility operational by Aug 2026 increasing capacity 2.5x.

Risks

High client concentration with top 10 clients contributing 49% of revenue; margin compression due to front-loaded employee costs.

Source

Earnings Call filed with NSE, NSE: INFLUX. Summary written with AI assistance from the document.

Read the document ↗

Influx Healthtech Ltd: key numbers

Share price
₹253.90
Market cap
₹587.8 Cr
Revenue (annual)
₹146.8 Cr
Net profit (annual)
₹20.54 Cr
P/E (TTM)
28.6×Sector 43.8×
Promoter holding
73.53%
FII holding
0.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Influx Healthtech Ltd

All →